Slow releasing ranolazine micro pill

Abstract

The present invention discloses one kind of slow releasing ranolazine micro pill including ranolazine and supplementary material. It consists of coating and isolating layer in 5-30 %, preferably in 10 % and pill core in 70-95 %, preferably in 90 %. The slow releasing ranolazine micro pill is tested to have release amount of 20-40 % within 2 hr, 50-80 % within 6 hr, and 80-100 % within 12 hr.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to ranolazine sustained-release pellets. Background technique [0002] Sustained-release preparations are one of the fastest-growing preparations in recent years. Sustained-release preparations can release drugs slowly according to certain rules, and maintain effective drug concentrations in the body for a long time, so as to improve curative effect, prolong drug action time and reduce drug exposure. The purpose of adverse reactions, specifically, has three advantages: (1) For patients, drug sustained release technology can increase the efficacy of drugs, reduce adverse reactions, increase patient compliance and comfort, especially for the elderly, For children and patients who need long-term medication, sustained-release preparations can improve their medication compliance; (2) Drug sustained-release technology can improve drug compliance and treatment convenience, greatly reducin...

AI Technical Summary

Problems solved by technology

[0003] It can be known from the literature review that not all drugs are suitable for the development of sustained-release preparations, and only drugs with certain characteristics are suitable for the development of sustained-release drugs. Drugs that have no correlation with their efficacy should not be made into sustained-release preparations. Some concentration-dependent antibiotics, whose antibacterial effect depends on the peak concentration, are not suitable to be made into sustained-release preparations in principle, etc.; however, some drugs treat chronic diseases, frequently-occurring diseases, etc. It needs to maintain a relatively stable blood drug concentration for a long time, or the drug itself has the characteristics of rapid absorption and clearance, which causes unnecessary large-scale fluctuations in blood drug concentration and short action cycles, so that frequent administration is required in order to obtain appropriate treatment. Such drugs are suitable for developing into sustained-release preparations, and ranolazine belongs to the drugs with the above-mentioned characteristics. The document of Chinese Patent Application No. 99810835.9 discloses a technical scheme for developing ranolazine into sustained-release preparations. Oxyzine is the main drug, developed into sustained-release tablets, but sustained-release tablets have great defects, and may cause "burst release" of active ingredients due to small damage, which will reduce the drug safety of patients, and Sustained-release pellets can solve the problem of "drug burst release" very well. Although the above-mentioned application has some introductions to the preparation of sustained-release pellets in its priority patent, there is no in-depth study based on the characteristics of sustained-release pellets. The study simply disclosed that ranolazine can be prepared into sustained-release pellets